- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost Considerations Regarding Anticoagulant Therapy
During this segment, Michael A. Evans, BS, RPh, discusses the importance of initiating anticoagulation for patients at risk of developing thromboembolic complications. However, he recognizes that the costs of treating patients with anticoagulants, especially direct-acting oral anticoagulants, affect both patients and the health system.
Health systems need to have a process in place for recognizing and managing patients who are at risk for thromboembolic disease, says Mr Evans, and an appropriate management team and proper resources are essential to implementing this process.
When considering initiating treatment with an anticoagulant, healthcare professionals need to take into account the burden of cost on both patients and health systems, as high treatment cost may affect patient adherence, explains Mr Evans. Over time, cost has become more of a consideration for patients due to the introduction of the direct-acting oral anticoagulants, which are more expensive than warfarin.
Therefore, when evaluating treatment options with patients, Mr Evans suggests that healthcare professionals discuss the differences in costs between therapy options and ensure that patients are a part of the decision-making process.
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
